By screening a variety of benign and malignant pigment cell lesions using immunohistochemistry and quantitative reverse transcription PCR analysis, the authors have found that ETB is a marker of tumor progression in malignant melanoma and could be a clinically relevant target for the development of small molecules that can block ET. This evidence concerns the gene EDNRB and neoplasm.